Verified employee & interview reviews

Bharat Biotech Reviews

Hyderabad, Telangana

4.7/ 5

3 reviews

Bharat Biotech International Limited (BBIL) is a pioneering Indian multinational biotechnology company headquartered in Genome Valley, Hyderabad. Established in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, the company specializes in drug discovery, drug development, and the large-scale manufacture of vaccines and bio-therapeutics. Managed by Executive Chairman Dr. Krishna Ella, Managing Director Suchitra Ella, and CEO Ajayreddy Parakala, Bharat Biotech operates as a private enterprise focused on delivering affordable, safe, and high-quality healthcare solutions, particularly targeting neglected and emerging infectious diseases in developing nations. The company operates sophisticated, high-containment Biosafety Level 3 (BSL-3) manufacturing facilities in Hyderabad, which are engineered to handle complex viral and bacterial strains. Bharat Biotech maintains an extensive product portfolio consisting of over 19 vaccines and four biotherapeutics, with a distribution and regulatory presence spanning more than 125 countries. To date, the company has delivered over nine billion vaccine doses globally, supplying major international health bodies such as UNICEF and GAVI. Bharat Biotech is widely recognized for its robust research and development capabilities, supported by over 145 global patents. It achieved global prominence during the pandemic by developing COVAXIN, India's first indigenous COVID-19 vaccine, in collaboration with the Indian Council of Medical Research (ICMR). Beyond COVAXIN, the company has delivered several significant breakthroughs in global health, including Typbar TCV, the world's first clinically proven typhoid conjugate vaccine, and ROTAVAC, a highly effective, naturally attenuated rotavirus vaccine that drastically reduced childhood diarrhea hospitalizations. Its broader commercial product line includes Biopolio, Comvac, JENVAC, and vaccines for Rabies, Chikungunya, Zika, and Japanese Encephalitis. Furthermore, the company expanded into biotherapeutics with products like REGEN-D, a recombinant Epidermal Growth Factor utilized to treat diabetic foot ulcers and severe burns. Financially, Bharat Biotech maintains a highly resilient position. While the private entity's historical revenue figures reached approximately INR 8,148 crore (USD 850 million) during peak vaccine rollouts in fiscal year 2022, recent operational revenues stood at INR 1,462.9 crore for fiscal year 2025, driven by strong core vaccine portfolios like the rotavirus segment. The company maintains a strong liquidity profile and funds ongoing capital expansions, including a $75 million integrated Cell and Gene Therapy facility in Hyderabad, primarily through internal accruals. Looking forward, the company continues to advance its clinical pipeline, actively developing new vaccine candidates for cholera, shigella, malaria, and tuberculosis.